Analysis of amyloid and tau deposition in Alzheimer's disease using 11C-Pittsburgh compound B and 18F-THK 5351 positron emission tomography imaging

Chotipanich, Chanisa; Nivorn, Monchaya; Kunawudhi, Anchisa; Promteangtrong, Chetsadaporn; Jantarato, Attapon

doi:10.4103/wjnm.wjnm_50_20

Cited by 4 publications

(5 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two hundred eighty‐seven articles were excluded through the filter at the official PubMed website, and 1420 articles were further excluded by reading the titles and abstracts. After carefully reading the full text and supplementary materials and judging the accuracy and reliability of the extracted data, the final number of articles included in our study was 48 (Beach et al., 2014; Brück et al., 2013; Camus et al., 2012; Clark et al., 2012; Fleisher, 2011; Hatashita & Yamasaki, 2013; Hatashita et al., 2014; Hosokawa et al., 2015; Jack et al., 2012; Kaneko et al., 2014; Kerbage et al., 2015; Li et al., 2015; Mattsson et al., 2014; Mikhno et al., 2012; Newberg et al., 2012; Ng et al., 2007; Rabinovici et al., 2011; Saint‐Aubert et al., 2014; Tolboom et al., 2010; Trzepacz et al., 2014; Tzen et al., 2014; Vandenberghe et al., 2010; Villemagne et al., 2011, 2019; Alvarez et al., 2018; Ben Bouallegue et al., 2017; Chen et al., 2016; Dukart et al., 2016; Iaccarino et al., 2017; La Joie et al., 2019; Mielke et al., 2018; Oliveira et al., 2018; Ottoy et al., 2019; Park et al., 2019; Schreiber et al., 2015; Seo et al., 2017; Takahashi et al., 2017; Villeneuve et al., 2015; Wang, Chen, et al., 2016; Wang, Yi, et al., 2016; Xu et al., 2016; Zhang et al., 2017; Zwan et al., 2016, 2021; Chanisa et al., 2021; Kitajima et al., 2021; Lesman‐Segev et al., 2021; Peretti et al., 2019). The specific process of literature screening is detailed in Figure 1.…”

Section: Resultsmentioning

confidence: 99%

“…In quantitative analysis, the average global cortical SUVR threshold ranged from 1.2 to 1.5, but setting the global SUVR threshold higher than 1.4 was thought to miss many AD patients (Villeneuve et al, 2015). Chanisa et al (2021) mentioned that Aβ plaques tend to spread from the cerebral cortex to the cingulate and precuneus regions, whereas they also found the highest 11 C-PIB deposition in the anterior and posterior cingulate gyri. His study showed that making a diagnosis based on local SUVR achieved higher sensitivity and specificity than global SUVR, and that the cutoff values of regional SUVR (1.46-1.81) were higher than global.…”

Section: Discussionmentioning

confidence: 99%

“…Chanisa et al. ( 2021 ) mentioned that Aβ plaques tend to spread from the cerebral cortex to the cingulate and precuneus regions, whereas they also found the highest 11 C‐PIB deposition in the anterior and posterior cingulate gyri. His study showed that making a diagnosis based on local SUVR achieved higher sensitivity and specificity than global SUVR, and that the cutoff values of regional SUVR (1.46–1.81) were higher than global.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Amyloid‐β PET in Alzheimer's disease: A systematic review and Bayesian meta‐analysis

Ruan

Sun

2022

Brain and Behavior

View full text Add to dashboard Cite

Background: In recent years, longitudinal studies of Alzheimer's disease (AD) have been successively concluded. Our aim is to determine the efficacy of amyloid-β (Aβ) PET in diagnosing AD and early prediction of mild cognitive impairment (MCI) converting to AD. By pooling studies from different centers to explore in-depth whether diagnostic performance varies by population type, radiotracer type, and diagnostic approach, thus providing a more comprehensive theoretical basis for the subsequent widespread application of Aβ PET in the clinical setting.Methods: Relevant studies were searched through PubMed. The pooled sensitivities, specificities, DOR, and the summary ROC curve were obtained based on a Bayesian random-effects model. Results:Forty-eight studies, including 5967 patients, were included. Overall, the pooled sensitivity, specificity, DOR, and AUC of Aβ PET for diagnosing AD were 0.90, 0.80, 35.68, and 0.91, respectively. Subgroup analysis showed that Aβ PET had high sensitivity (0.91) and specificity (0.81) for differentiating AD from normal controls but very poor specificity (0.49) for determining AD from MCI. The pooled sensitivity and specificity were 0.84 and 0.62, respectively, for predicting the conversion of MCI to AD. The differences in diagnostic efficacy between visual assessment and quantitative analysis and between 11 C-PIB PET and 18 F-florbetapir PET were insignificant. Conclusions:The overall performance of Aβ PET in diagnosing AD is favorable, but the differentiation between MCI and AD patients should consider that some MCI may be at risk of conversion to AD and may be misdiagnosed. A multimodal diagnostic approach and machine learning analysis may be effective in improving diagnostic accuracy.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Amyloid‐β PET in Alzheimer's disease: A systematic review and Bayesian meta‐analysis

Ruan

Sun

2022

Brain and Behavior

View full text Add to dashboard Cite

show abstract

“…Therefore, the use of 18 F-THK5351 in the clinic still can provide information about tauopathies onset and development, helping to discriminate from other non-tau-related neurological disorders. In fact, 18 F-THK5351 is successfully used to diagnose AD when used in combination with other biomarkers such as automated brain volumetry on MRI [39] or 11 C-Pittsburgh compound B [40]. Additionally, a combination of tau tracers may be best for identifying the disease process underlying tauopathies.…”

Section: Discussionmentioning

confidence: 99%

Longitudinal Assessment of Tau-Associated Pathology by 18F-THK5351 PET Imaging: A Histological, Biochemical, and Behavioral Study

et al. 2021

View full text Add to dashboard Cite

Several common and debilitating neurodegenerative disorders are characterized by the intracellular accumulation of neurofibrillary tangles (NFTs), which are composed of hyperphosphorylated tau protein. In Alzheimer’s disease (AD), NFTs are accompanied by extracellular amyloid-beta (Aβ), but primary tauopathy disorders are marked by the accumulation of tau protein alone, including forms of frontotemporal dementia (FTD), corticobasal degeneration (CBD), and progressive supranuclear palsy (PSP), among others. 18F-THK5351 has been reported to bind pathological tau as well as associated reactive astrogliosis. The goal of this study was to validate the ability of the PET tracer 18F-THK5351 to detect early changes in tau-related pathology and its relation to other pathological hallmarks. We demonstrated elevated in vivo 18F-THK5351 PET signaling over time in transgenic P301S tau mice from 8 months that had a positive correlation with histological and biochemical tau changes, as well as motor, memory, and learning impairment. This study indicates that 18F-THK5351 may help fill a critical need to develop PET imaging tracers that detect aberrant tau aggregation and related neuropathology in order to diagnose the onset of tauopathies, gain insights into their underlying pathophysiologies, and to have a reliable biomarker to follow during treatment trials.

show abstract

“…The proposed [ 11 C]PiB cut-off for regional SUVR was approximately 1.46-1.81 in their study yielded sensitivity ranging from 81.25% to 93.75%, and specificity of 100% (CI 0.82-1.00). 64 Another study on the additional diagnostic value of molecular imaging using [ 11 C]PiB amyloid PET together with [ 18 F] FDG metabolic PET and [ 18 F]THK5351 Tau PET on the diagnosis of dementia subtypes found primary diagnosis change in 60% of patients and the combined PET scan information was able to solve 95.2% pre-PET diagnostic dilemmas. 65 To the best of our knowledge, the clinical performance of [ 18 F]Florbetaben PET scan at The National Cyclotron and PET Centre has not been published yet.…”

Section: Clinical and Research Applications At The National Cyclotron...mentioning

confidence: 99%

Amyloid PET Radiopharmaceuticals and Imaging for Clinical and Research Applications in Thailand

Siriprapa,

Thientunyakit,

Gelovani

2023

Siriraj Med J

View full text Add to dashboard Cite

In the past two decades, the research community has focused on defining reliable molecular biomarkers for the early diagnosis of Alzheimer's disease (AD). Several PET radiopharmaceuticals have been developed and gained regulatory approval for the non-invasive detection of Aβ amyloid deposits in the brain. Nowadays, there are several PET imaging tracers available in Thailand for amyloid imaging including [11C]PiB, [18F]Florbetapir, and [18F]Florbetaben. This review provides a summary of commonly used amyloid PET radiopharmaceuticals, focusing on the available radiopharmaceuticals in Thailand and the experiences of using amyloid PET radiopharmaceuticals and imaging for clinical and research applications at Siriraj Hospital.

show abstract

Analysis of amyloid and tau deposition in Alzheimer's disease using 11C-Pittsburgh compound B and 18F-THK 5351 positron emission tomography imaging

Cited by 4 publications

References 29 publications

Amyloid‐β PET in Alzheimer's disease: A systematic review and Bayesian meta‐analysis

Amyloid‐β PET in Alzheimer's disease: A systematic review and Bayesian meta‐analysis

Longitudinal Assessment of Tau-Associated Pathology by 18F-THK5351 PET Imaging: A Histological, Biochemical, and Behavioral Study

Amyloid PET Radiopharmaceuticals and Imaging for Clinical and Research Applications in Thailand

Contact Info

Product

Resources

About